Search research articles
Contact Us
Filters
Showing results (61-70 of 145) with videos related to
Page
of 15
Sort By:
Journal of Geriatric Oncology
|
October 24, 2020
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)
Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, et al.
The Journal of Antimicrobial Chemotherapy
|
June 21, 2014
Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey
Livio Pagano, Luisa Verga, Alessandro Busca, et al.
Hematological Oncology
|
September 19, 2020
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia
Erika Borlenghi, Chiara Cattaneo, Elisa Cerqui, et al.
British Journal of Haematology
|
October 21, 2020
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial
Andrés J M Ferreri, Chiara Cattaneo, Arben Lleshi, et al.
Blood Advances
|
May 17, 2022
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma
Andrés J M Ferreri, Piera Angelillo, Federico Erbella, et al.
Leukemia & Lymphoma
|
May 17, 2017
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy
Alessandro Busca, Federica Lessi, Luisa Verga, et al.
Cancers
|
January 23, 2024
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda
Giuseppe Rossi, Erika Borlenghi, Patrizia Zappasodi, et al.
Cancer Medicine
|
December 31, 2015
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients
Michele Malagola, Cristina Skert, Erika Borlenghi, et al.
Blood
|
November 16, 2020
Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88
Antonio Sacco, Cinzia Federico, Arianna Giacomini, et al.
Clinical and Translational Science
|
July 29, 2023
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
Pierantonio Menna, Francesco Marchesi, Chiara Cattaneo, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 145) with videos related to
Sort By:
Page
of 15
Journal of Geriatric Oncology
|
October 24, 2020
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)
Erika Borlenghi, Chiara Pagani, Patrizia Zappasodi, et al.
The Journal of Antimicrobial Chemotherapy
|
June 21, 2014
Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey
Livio Pagano, Luisa Verga, Alessandro Busca, et al.
Hematological Oncology
|
September 19, 2020
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia
Erika Borlenghi, Chiara Cattaneo, Elisa Cerqui, et al.
British Journal of Haematology
|
October 21, 2020
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial
Andrés J M Ferreri, Chiara Cattaneo, Arben Lleshi, et al.
Blood Advances
|
May 17, 2022
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma
Andrés J M Ferreri, Piera Angelillo, Federico Erbella, et al.
Leukemia & Lymphoma
|
May 17, 2017
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy
Alessandro Busca, Federica Lessi, Luisa Verga, et al.
Cancers
|
January 23, 2024
Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination-Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda
Giuseppe Rossi, Erika Borlenghi, Patrizia Zappasodi, et al.
Cancer Medicine
|
December 31, 2015
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients
Michele Malagola, Cristina Skert, Erika Borlenghi, et al.
Blood
|
November 16, 2020
Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88
Antonio Sacco, Cinzia Federico, Arianna Giacomini, et al.
Clinical and Translational Science
|
July 29, 2023
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study
Pierantonio Menna, Francesco Marchesi, Chiara Cattaneo, et al.
Page
of 15